Share
Dave Gardner
Incyte has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer (CSO).
In this role, Mr. Gardner will be a key member of the Executive Leadership Team, overseeing the company’s strategy and business development initiatives.
Mr. Gardner brings over 20 years of experience in pharmaceutical and biotechnology investing and advisory. He most recently served as Partner on the Therapeutics Team at Rock Springs Capital Management, where he led strategy across Oncology, Neurology, Immunology, and Rare Diseases. Previously, he spent a decade at BlackRock as Vice President and Equity Research Analyst, focusing on the Health Care sector.
He holds an Executive MBA from Columbia Business School and a bachelor’s degree from the University of Virginia’s McIntire School of Commerce.
In connection with this leadership transition, Vijay Iyengar, M.D., Executive Vice President and Head of Global Medical Affairs and Product and Partnership Strategy, will be retiring after nine years with Incyte. Dr. Iyengar will provide transitional support to Mr. Gardner through the end of the year, ensuring continuity in strategy and business operations.
This appointment underscores Incyte’s focus on strategic growth and innovation in the pharmaceutical and biotechnology sectors.
